CF
MDGL icon

Centaurus Financial’s Madrigal Pharmaceuticals MDGL Stock Holding History

Centaurus Financial’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Buy
721
+12
+2% +$6.15K 0.02% 651
2026
Q1 		$371K Hold
709
– – 0.02% 611
2025
Q4 		$413K Hold
709
– – 0.02% 574
2025
Q3 		$325K Buy
709
+34
+5% +$12.7K 0.02% 654
2025
Q2 		$204K Sell
675
-15
-2% -$4.47K 0.01% 717
2025
Q1 		$229K Hold
690
– – 0.01% 643
2024
Q4 		$213K Buy
690
+79
+13% +$22.2K 0.01% 646
2024
Q3 		$130K Buy
611
+28
+5% +$7.16K 0.01% 770
2024
Q2 		$163K Buy
+583
New +$139K 0.01% 657

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Centaurus Financial's MDGL Position: Q2 2026 in Review

Centaurus Financial increased its Madrigal Pharmaceuticals (MDGL) stake by 1.7% in Q2 2026, buying an estimated $6.15K and bringing the position to 721 shares worth $387K. The position accounts for 0.02% of the portfolio, ranked #651.

Centaurus Financial first reported a position in MDGL in Q2 2024 and has held it in 9 quarters since. The position peaked at $413K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Centaurus Financial held 721 shares of Madrigal Pharmaceuticals worth $387K as of Q2 2026.
  • Centaurus Financial bought 12 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $6.15K.
  • Madrigal Pharmaceuticals made up 0.02% of Centaurus Financial's portfolio in Q2 2026, its #651 holding.
  • Centaurus Financial first reported a position in Madrigal Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Centaurus Financial's Madrigal Pharmaceuticals position peaked at $413K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Centaurus Financial's 13F filing for Q2 2026, filed 17 Aug 2026.